During the Excellence Appraisal, all organizations would demonstrate the capability to collect and analyze post-launch Real World Performance (RWP) data, whether by instrumenting their SaMD products to generate needed data, or by leveraging alternative data sources. Therefore, FDA expects that these organizations will consistently collect and analyze post-launch data related…